trandolapril (mavik) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. Trandolapril is marketed by Abbott Laboratories under the brand name Mavik.   NCATS

Chemistry

  • SMILES: C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(O)=O
  • InChIKey: AHYHTSYNOHNUSH-HXFGRODQSA-N
  • Mol. Mass: 402.484
  • ALogP: 2.29
  • ChEMBL Molecules:
    trandolaprilat  
    trandolapril  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.0656 - $0.3456

United States

$0.2061 - $0.2876
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( trandolapril (mavik), verapamil (calan) )

Alternative names

1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1h-indol-2-carboxylic acid | abbott brand of trandolapril | alter brand of trandolapril | aventis brand of trandolapril | aventis pharma brand of trandolapril | gopten | hoechst brand of trandolapril | indolapril | knoll brand of trandolapril | mavik | odrik | ru44570 | ru 44570 | ru-44570 | trandolapril | trandolaprilum | udrik

Organizations (28)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (4)


 

Heart Failure (approved 1996)

Hypertension

Myocardial Infarction

Ventricular Dysfunction, Left

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Aortic Valve Stenosis (Phase 4)

Coronary Artery Disease (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 4)

Heart Failure (Phase 4)

Hypertension (Phase 4)

Hypotension (Phase 4)

Metabolic Syndrome (Phase 4)

Obesity (Phase 3)

Proteinuria (Phase 4)

Ventricular Dysfunction, Left (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue